CMPX
Compass Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.38
+0.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 850.0K | — | — |
| Cost of Revenue | 738.0K | 1.5M | — | — | — |
| Gross Profit | (738.0K) | (1.5M) | 850.0K | — | — |
| Operating Expenses | |||||
| R&D Expense | 59.5M | 56.0M | 42.3M | 38.1M | 30.0M |
| SG&A Expense | 21.3M | 16.9M | 15.1M | 12.2M | 11.7M |
| General & Admin Expense | 21.6M | 16.9M | 15.1M | 12.2M | 11.7M |
| Selling & Marketing Expense | (353.0K) | — | — | — | — |
| Other Expenses | (370.0K) | (1.5M) | — | — | — |
| Total Operating Expenses | 80.3M | 71.4M | 57.5M | 50.4M | 41.7M |
| Cost and Expenses | 81.1M | 72.8M | 57.5M | 50.4M | 41.7M |
| Operating Income (EBIT) | (81.1M) | (72.8M) | (56.6M) | (50.4M) | (41.7M) |
| Non-Operating | |||||
| Interest Income | 7.6M | 6.3M | 7.3M | 7.9M | 2.4M |
| Interest Expense | — | — | — | — | 2.4M |
| Net Interest Income | 7.6M | 6.3M | 7.3M | 7.9M | — |
| Other Non-Op Income/Expense | 7.6M | 6.3M | 7.3M | 7.9M | 2.4M |
| Non-Operating Income (excl Interest) | (7.6M) | (6.3M) | (7.3M) | (7.9M) | (4.8M) |
| EBT (Pre-Tax Income) | (73.4M) | (66.5M) | (49.4M) | (42.5M) | (39.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (73.4M) | (66.5M) | (49.4M) | (42.5M) | (39.2M) |
| Earnings from Cont. Ops | (73.4M) | (66.5M) | (49.4M) | (42.5M) | (39.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (73.4M) | (66.5M) | (49.4M) | (42.5M) | (39.2M) |
| Per Share | |||||
| Basic EPS | ($0.42) | ($0.42) | ($0.36) | ($0.33) | ($0.35) |
| Diluted EPS | ($0.42) | ($0.42) | ($0.36) | ($0.33) | ($0.35) |
| Revenue Per Share | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 186.8M | 157.7M | 137.1M | 127.0M | 105.2M |
| Diluted Shares Outstanding | 186.8M | 157.7M | 137.1M | 127.0M | 105.2M |
| Profitability Metrics | |||||
| EBITDA | (72.7M) | (65.0M) | (47.6M) | (40.6M) | (35.0M) |
| D&A | 778.0K | 1.5M | 1.8M | 1.9M | 1.9M |
| EBIT | (73.4M) | (66.5M) | (49.4M) | (42.5M) | (36.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026